Host and Bacterial Factors in Disease due to H. Pylori

幽门螺杆菌疾病的宿主和细菌因素

基本信息

  • 批准号:
    7730235
  • 负责人:
  • 金额:
    $ 35.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1998
  • 资助国家:
    美国
  • 起止时间:
    1998-05-01 至 2011-06-30
  • 项目状态:
    已结题

项目摘要

Helicobacter pylori remains the most prevalent infectious disease in the world, with up to100% of people colonized in some populations. Disease due to H. pylori is variable, however: only a minority of infected individuals develops clinical disease. It has become increasingly clear that this variability is attributable to differences in host immune response, and that understanding the immune mechanisms that contribute to disease will be essential for controlling gastritis and the subsequent sequelae such as peptic ulcer disease and cancer. Our laboratory uses an established adoptive transfer model to study the adaptive immune response to H. pylori. CD4 (helper) T cells are necessary and sufficient to induce disease in H. pylori infected mice, and regulatory T cells suppress gastritis. Infection is associated with IFN_ but recent data indicate that, contrary to previous assumptions, several immune pathways including Th1, Th17, and possibly others contribute to gastritis due to H. pylori. Our central hypothesis is that the balance between Th-1, Th-17, and T regulatory cells determines the outcome of gastritis due to H. pylori. Our overall goals are to determine the role of cross-regulation between Th-1 and Th-17 in regulation of gastritis and to determine the mechanism of Treg cells in suppression of Th-1 independent and Th-17 independent gastritis. The two specific aims are: Aim 1: To determine the interactions between IFN_ and IL-17 in H. pylori gastritis. Aim 2: To determine the mechanism by which CD4CD25Foxp3+ regulatory T cells regulate Th1- or Th17- independent inflammation due to H. pylori. In this revision we have eliminated long-term experiments and thereby decreased the number of mice to be used. This will allow us to hire additional staff to ensure rapid completion of the remaining experiments. With these changes we fully expect to complete these experiments in 2 years.
幽门螺杆菌仍然是世界上最流行的传染病,在某些人群中高达100%的人定植。疾病由于H。然而,幽门螺杆菌是可变的:只有少数感染个体发展为临床疾病。越来越清楚的是,这种变异性可归因于宿主免疫反应的差异,并且理解有助于疾病的免疫机制对于控制胃炎和随后的后遗症如消化性溃疡疾病和癌症将是至关重要的。本实验室利用已建立的过继转移模型研究了H.幽门。CD 4(辅助)T细胞是诱导H. pylori感染的小鼠,调节性T细胞抑制胃炎。感染与IFN-γ有关,但最近的数据表明,与以前的假设相反,包括Th 1,Th 17在内的几种免疫途径以及可能的其他途径导致H.幽门。我们的中心假设是Th-1、Th-17和调节性T细胞之间的平衡决定了H.幽门。我们的总体目标是确定Th-1和Th-17之间的交叉调节在胃炎调节中的作用,并确定Treg细胞抑制Th-1非依赖性胃炎和Th-17非依赖性胃炎的机制。目的1:研究IFN-γ与IL-17在H.幽门胃炎目的2:探讨CD 4CD 25 Foxp 3+调节性T细胞对H.幽门。在这次修订中,我们取消了长期实验,从而减少了使用的小鼠数量。这将使我们能够雇用更多的工作人员,以确保迅速完成剩余的实验。通过这些变化,我们完全期望在两年内完成这些实验。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KATHRYN A. EATON其他文献

KATHRYN A. EATON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KATHRYN A. EATON', 18)}}的其他基金

The role of prophage life cycle in Stx production and disease due to EHEC
原噬菌体生命周期在 Stx 产生和 EHEC 引起的疾病中的作用
  • 批准号:
    8416401
  • 财政年份:
    2012
  • 资助金额:
    $ 35.95万
  • 项目类别:
The role of prophage life cycle in Stx production and disease due to EHEC
原噬菌体生命周期在 Stx 产生和 EHEC 引起的疾病中的作用
  • 批准号:
    8243170
  • 财政年份:
    2012
  • 资助金额:
    $ 35.95万
  • 项目类别:
Recombinant murine IL-10 produced in situ by H. pylori
由幽门螺杆菌原位产生的重组鼠 IL-10
  • 批准号:
    6833463
  • 财政年份:
    2003
  • 资助金额:
    $ 35.95万
  • 项目类别:
Recombinant murine IL-10 produced in situ by H. pylori
由幽门螺杆菌原位产生的重组鼠 IL-10
  • 批准号:
    6709130
  • 财政年份:
    2003
  • 资助金额:
    $ 35.95万
  • 项目类别:
Host and Bacterial Factors in Disease due to H. pylori
幽门螺杆菌疾病的宿主和细菌因素
  • 批准号:
    7231007
  • 财政年份:
    1998
  • 资助金额:
    $ 35.95万
  • 项目类别:
HOST AND BACTERIAL FACTORS IN DISEASE DUE TO H PYLORI
幽门螺杆菌引起的疾病的宿主和细菌因素
  • 批准号:
    2887829
  • 财政年份:
    1998
  • 资助金额:
    $ 35.95万
  • 项目类别:
Host and Bacterial Factors in Disease due to H. pylori
幽门螺杆菌疾病的宿主和细菌因素
  • 批准号:
    7066068
  • 财政年份:
    1998
  • 资助金额:
    $ 35.95万
  • 项目类别:
Host and Bacterial Factors in Disease due to H. pylori
幽门螺杆菌疾病的宿主和细菌因素
  • 批准号:
    6731771
  • 财政年份:
    1998
  • 资助金额:
    $ 35.95万
  • 项目类别:
HOST AND BACTERIAL FACTORS IN DISEASE DUE TO H PYLORI
幽门螺杆菌引起的疾病的宿主和细菌因素
  • 批准号:
    2689786
  • 财政年份:
    1998
  • 资助金额:
    $ 35.95万
  • 项目类别:
HOST AND BACTERIAL FACTORS IN DISEASE DUE TO H PYLORI
幽门螺杆菌引起的疾病的宿主和细菌因素
  • 批准号:
    6171006
  • 财政年份:
    1998
  • 资助金额:
    $ 35.95万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 35.95万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 35.95万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 35.95万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.95万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 35.95万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 35.95万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 35.95万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 35.95万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 35.95万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 35.95万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了